Oric Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company complies with various federal, state, and foreign healthcare laws and regulations affecting its business arrangements related to research, sales, marketing, and distribution of approved products. Relevant laws include the federal Anti-Kickback Statute (AKS), the Patient Protection and Affordable Care Act (ACA), the civil False Claims Act (FCA), the Federal Health Insurance Portability and Accountability Act (HIPAA) and its amendments, and the federal Physician Payments Sunshine Act. These laws govern interactions with healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program, and mandate reporting of payments and transfers of value to healthcare professionals and teaching hospitals. The company’s activities involve prescription drug and medical device manufacturers, federal healthcare programs, physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—non-physician healthcare professionals such as physician assistants and nurse practitioners, and teaching hospitals.
: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to challenge clinicians due to inherent and acquired therapeutic resistance. In recent developments, ORIC Pharmaceuticals has reported promising results from its ongoing Phase 1b clinical trial evaluating ORIC-944, an innovative, experimental therapy designed to overcome therapeutic resistance mechanisms in mCRPC. Emerging data highlight the drug s potential efficacy and safety, positioning ORIC-944 as a potentially best-in-class treatment option. mCRPC represents a critical stage in prostate cancer progression, often characterized by resistance to existing therapies, including androgen receptor (AR) inhibitors...
ORIC Pharmaceuticals Set to Illuminate Investor Conferences Amidst Promising Therapeutic Developments In a strategic move indicative of its commitment to transparency and stakeholder engagement, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced its participation in several upcoming investor conferences in April 2025. Headquartered in South San Francisco and with an office in San Diego, ORIC Pharmaceuticals stands at the forefront of oncology, focusing on innovative treatments designed to tackle the challenging mechanisms of therapeutic resistance that often thwart cancer treatments. The company’s management team will take this opportunity to share insights into its clinical pipeline, which is cente...
In recent developments within the pharmaceutical landscape, ORIC Pharmaceuticals Inc. has outlined its strategic registrational clinical development plans aimed at enhancing its lead programs while simultaneously extending its cash runway. At the heart of this initiative is a clear focus on ORIC-944 and ORIC-114, two candidates poised to address indications with robust clinical validation and dire unmet medical needs.Despite setting ambitious developmental goals, the journey for ORIC Pharmaceuticals has not been devoid of hurdles. Over the past week, the company’s shares have underperformed relative to both customers and suppliers, exhibiting a concerning decline of -13.1%, as opposed to the -1.51% dip exp...
Potential Game-Changer in Prostate Cancer Treatment: ORIC Pharmaceuticals Innovative CollaborationsIn a significant stride towards advancing the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), ORIC Pharmaceuticals has announced a series of clinical collaborations with strategic partners to evaluate ORIC-944 in combination with established androgen receptor (AR) inhibitors. This promising development involves testing the potential best-in-class PRC2 inhibitor, ORIC-944, in conjunction with darolutamide and apalutamide.Aligning with these recent endeavors, ORIC Pharmaceuticals has provided robust preclinical data at the 2024 American Association for Cancer Research (AACR) Ann...
ORIC Pharmaceuticals Makes Strides in Advancing Targeted Therapies for Mutated NSCLC, Metastatic Prostate Cancer, and Multiple MyelomaORIC Pharmaceuticals, a renowned clinical-stage biopharmaceutical company specializing in developing innovative therapies for cancer patients, has recently achieved significant milestones in their ongoing Phase 1b trials for three of their promising drug candidates. The first patients have been successfully dosed across three expansion cohorts in the Phase 1b trial of ORIC-114 for the treatment of mutated non-small cell lung cancer (NSCLC). Additionally, ORIC Pharmaceuticals has also revealed initial Phase 1b data for ORIC-944 in metastatic prostate cancer and promising Phase ...
Oric Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company complies with various federal, state, and foreign healthcare laws and regulations affecting its business arrangements related to research, sales, marketing, and distribution of approved products. Relevant laws include the federal Anti-Kickback Statute (AKS), the Patient Protection and Affordable Care Act (ACA), the civil False Claims Act (FCA), the Federal Health Insurance Portability and Accountability Act (HIPAA) and its amendments, and the federal Physician Payments Sunshine Act. These laws govern interactions with healthcare programs such as Medicare, Medicaid, and the Children’s Health Insurance Program, and mandate reporting of payments and transfers of value to healthcare professionals and teaching hospitals. The company’s activities involve prescription drug and medical device manufacturers, federal healthcare programs, physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—non-physician healthcare professionals such as physician assistants and nurse practitioners, and teaching hospitals.
Sources:
Oric Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Oric Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Oric Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
